Point72 Asia Singapore Pte. Ltd. Sells 3,724 Shares of CG Oncology, Inc. (NASDAQ:CGON)

Point72 Asia Singapore Pte. Ltd. decreased its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 75.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,209 shares of the company’s stock after selling 3,724 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in CG Oncology were worth $38,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of CGON. BNP Paribas Financial Markets purchased a new position in CG Oncology in the 1st quarter worth approximately $492,000. Capstone Investment Advisors LLC purchased a new position in CG Oncology in the first quarter worth $806,000. TimesSquare Capital Management LLC purchased a new position in CG Oncology in the first quarter worth $9,837,000. Vanguard Group Inc. bought a new position in CG Oncology in the first quarter valued at $97,678,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in CG Oncology during the first quarter valued at about $102,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CG Oncology

In other news, Director Hong Fang Song sold 650,455 shares of CG Oncology stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total value of $23,000,088.80. Following the sale, the director now directly owns 586,982 shares in the company, valued at approximately $20,755,683.52. The sale was disclosed in a filing with the SEC, which is available through this link.

Analyst Upgrades and Downgrades

CGON has been the subject of several research analyst reports. Roth Mkm assumed coverage on CG Oncology in a research note on Tuesday, August 27th. They set a “buy” rating and a $65.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of CG Oncology in a research note on Tuesday, September 17th. Royal Bank of Canada began coverage on shares of CG Oncology in a report on Monday, September 23rd. They issued an “outperform” rating and a $66.00 price objective for the company. Bank of America assumed coverage on shares of CG Oncology in a report on Friday, June 28th. They set a “buy” rating and a $65.00 target price on the stock. Finally, Roth Capital upgraded shares of CG Oncology to a “strong-buy” rating in a research report on Tuesday, August 27th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $64.43.

CG Oncology Trading Down 0.4 %

NASDAQ:CGON opened at $37.73 on Tuesday. The company has a fifty day moving average of $35.37 and a 200 day moving average of $35.27. CG Oncology, Inc. has a 52 week low of $25.77 and a 52 week high of $50.23.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.14. The firm had revenue of $0.11 million for the quarter. On average, sell-side analysts predict that CG Oncology, Inc. will post -1.47 EPS for the current year.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.